miRNA/miRNA cluster | Childhood cancer type* | Comments | Ref | |
---|---|---|---|---|
miR-16 | OS | Differentially expressed compared to healthy bone tissue | [103] | |
miR-29b | OS | Differentially expressed compared to healthy bone tissue | [103] | |
miR-142-5p | OS | Differentially expressed compared to healthy bone tissue | [103] | |
miR-34 family | miR-34a, miR-34b, miR-34c | NB, OS | Targets MYCN, identified as tumour suppressors, often found in 1p deletion in MNA NB tumours, targeted by p53 | |
miR-451 | OS | Higher expression in pre-treatment samples, corresponded with positive response to chemotherapy | [103] | |
miR-15b | OS | Higher expression in pre-treatment samples, corresponded with positive response to chemotherapy | [103] | |
miR-125b-1-3p | NB | Lower expression may be associated with chemoresistence | [86] | |
miR-199a-3p | OS | Differentially expressed in OS cell lines, regulation of proliferation in osteoblasts, acts as tumour suppressor | [96] | |
miR-127-3p | OS | Differentially expressed in OS cell lines, regulation of proliferation in osteoblasts, acts as tumour suppressor | [96] | |
miR-370 | OS | Differentially expressed in OS cell lines, regulation of proliferation in osteoblasts, acts as tumour suppressor | [96] | |
Let-7 family | Let-7a, Let-7b, Let-7c, Let-7d, Let-7e, Let-7f, Let-7Â g, Let-7i, miR-98 | WT | Impaired expression observed due to DICER1 and DROSHA mutations, regulators of MYCN and LIN28 | |
miR-195 | HB | Differentially expressed in fetal subtype compared to surrounding normal liver tissue | [121] | |
miR-210 | HB | Differentially expressed in fetal subtype compared to surrounding normal liver tissue | [121] | |
miR-214 | HB | Differentially expressed in fetal subtype compared to surrounding normal liver tissue | [121] | |
miR-124 | PA | Differentially expressed in PA tumours compared to normal brain tissue, targets putative oncogenes, enriched in brain tissue | ||
miR-218 | MB | Low expression observed, targets include pathways involved in cell cycle, metabolism and motility, CDK6 is target of interest (upregulates cell cycle progression and blocks differentiation) | ||
miR-497 | NB | Targets key cell cycle regulator WEE1. Low levels seen in high risk MNA tumours which also display high levels of WEE1. It is a candidate tumour suppressor and may be useful as a therapeutic target. | [85] |